Cargando…

Effects of Astragalus Polysaccharides Nanoparticles on Cerebral Thrombosis in SD Rats

OBJECTIVE: To investigate the efficacy and improvement of Astragalus polysaccharides (APS) and APS-nano on cerebral thrombosis in rats. METHODS: A total of 72 SD rats were randomly divided into NC group, Model group, APS-Nano group, and APS group. The cerebral thrombosis Model of SD rats was establi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Qian, Shi, Pengqiang, Lin, Cuiling, Ma, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785889/
https://www.ncbi.nlm.nih.gov/pubmed/33425879
http://dx.doi.org/10.3389/fbioe.2020.616759
_version_ 1783632518422986752
author Sun, Qian
Shi, Pengqiang
Lin, Cuiling
Ma, Jing
author_facet Sun, Qian
Shi, Pengqiang
Lin, Cuiling
Ma, Jing
author_sort Sun, Qian
collection PubMed
description OBJECTIVE: To investigate the efficacy and improvement of Astragalus polysaccharides (APS) and APS-nano on cerebral thrombosis in rats. METHODS: A total of 72 SD rats were randomly divided into NC group, Model group, APS-Nano group, and APS group. The cerebral thrombosis Model of SD rats was established by injecting compound thrombus inducer into the internal carotid artery. After 14 days of different intervention treatments, the TTC staining of brain tissue were performed, and A/left brain wet weight ratio, left brain/right brain wet weight ratio, blood rheology indexes, and coagulation function indexes of cerebral thrombosis were measured. ELISA was used to measure the contents of thromboxane 2 (TXB2), 6-keto-prostaglandin F1α (6-Keto-PGF1α), tissue factor (TF), neuron-specific enolase (NSE), S-100β, catenin (CAT), superoxide dismutase (SOD), as well as malondialdehyde (MDA). The binding specificity between miR-885-3p and TF was verified by the double-luciferin reporting experiment, and western blot was used to measure the expression level of TF protein. RESULTS: Compared with the Model group, after treatment with APS-nano or APS, the ratio of left brain/right brain wet weight decreased significantly. Whole blood low shear viscosity (WBLSV), whole blood high shear viscosity (WBHSV), plasma viscosity (PV), and erythrocyte aggregation index (Arbc) was all reduced. In addition, prothrombin time (PT) and activated partial thromboplastin time (APTT) were increased, and fibrinogen (FIB) content was decreased. The expression of TXB2, 6-Keto-PGF1α, and TF showed a downward trend. Similarly, the expression of TF protein was decreased. Furthermore, the contents of NSE and S-100β proteins were all decreased, whereas the contents of CAT and SOD were increased, and the contents of MDA was decreased. At the same dose, compared with APS treatment, APS-nano treatment had a significant inhibitory effect on cerebral thrombosis in rats. Finally, we found that TF is a target gene of miR-885-3p and specifically binds to miR-885-3p. CONCLUSION: APS has a significant inhibitory effect on the formation of cerebral thrombosis induced by compound thrombus inducers. Moreover, APS-nano has a more significant inhibitory effect on cerebral thrombosis. Meanwhile, the regulation of miR-885-3p regulating TF expression may be related to the occurrence of cerebral thrombosis.
format Online
Article
Text
id pubmed-7785889
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77858892021-01-07 Effects of Astragalus Polysaccharides Nanoparticles on Cerebral Thrombosis in SD Rats Sun, Qian Shi, Pengqiang Lin, Cuiling Ma, Jing Front Bioeng Biotechnol Bioengineering and Biotechnology OBJECTIVE: To investigate the efficacy and improvement of Astragalus polysaccharides (APS) and APS-nano on cerebral thrombosis in rats. METHODS: A total of 72 SD rats were randomly divided into NC group, Model group, APS-Nano group, and APS group. The cerebral thrombosis Model of SD rats was established by injecting compound thrombus inducer into the internal carotid artery. After 14 days of different intervention treatments, the TTC staining of brain tissue were performed, and A/left brain wet weight ratio, left brain/right brain wet weight ratio, blood rheology indexes, and coagulation function indexes of cerebral thrombosis were measured. ELISA was used to measure the contents of thromboxane 2 (TXB2), 6-keto-prostaglandin F1α (6-Keto-PGF1α), tissue factor (TF), neuron-specific enolase (NSE), S-100β, catenin (CAT), superoxide dismutase (SOD), as well as malondialdehyde (MDA). The binding specificity between miR-885-3p and TF was verified by the double-luciferin reporting experiment, and western blot was used to measure the expression level of TF protein. RESULTS: Compared with the Model group, after treatment with APS-nano or APS, the ratio of left brain/right brain wet weight decreased significantly. Whole blood low shear viscosity (WBLSV), whole blood high shear viscosity (WBHSV), plasma viscosity (PV), and erythrocyte aggregation index (Arbc) was all reduced. In addition, prothrombin time (PT) and activated partial thromboplastin time (APTT) were increased, and fibrinogen (FIB) content was decreased. The expression of TXB2, 6-Keto-PGF1α, and TF showed a downward trend. Similarly, the expression of TF protein was decreased. Furthermore, the contents of NSE and S-100β proteins were all decreased, whereas the contents of CAT and SOD were increased, and the contents of MDA was decreased. At the same dose, compared with APS treatment, APS-nano treatment had a significant inhibitory effect on cerebral thrombosis in rats. Finally, we found that TF is a target gene of miR-885-3p and specifically binds to miR-885-3p. CONCLUSION: APS has a significant inhibitory effect on the formation of cerebral thrombosis induced by compound thrombus inducers. Moreover, APS-nano has a more significant inhibitory effect on cerebral thrombosis. Meanwhile, the regulation of miR-885-3p regulating TF expression may be related to the occurrence of cerebral thrombosis. Frontiers Media S.A. 2020-12-23 /pmc/articles/PMC7785889/ /pubmed/33425879 http://dx.doi.org/10.3389/fbioe.2020.616759 Text en Copyright © 2020 Sun, Shi, Lin and Ma. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Sun, Qian
Shi, Pengqiang
Lin, Cuiling
Ma, Jing
Effects of Astragalus Polysaccharides Nanoparticles on Cerebral Thrombosis in SD Rats
title Effects of Astragalus Polysaccharides Nanoparticles on Cerebral Thrombosis in SD Rats
title_full Effects of Astragalus Polysaccharides Nanoparticles on Cerebral Thrombosis in SD Rats
title_fullStr Effects of Astragalus Polysaccharides Nanoparticles on Cerebral Thrombosis in SD Rats
title_full_unstemmed Effects of Astragalus Polysaccharides Nanoparticles on Cerebral Thrombosis in SD Rats
title_short Effects of Astragalus Polysaccharides Nanoparticles on Cerebral Thrombosis in SD Rats
title_sort effects of astragalus polysaccharides nanoparticles on cerebral thrombosis in sd rats
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785889/
https://www.ncbi.nlm.nih.gov/pubmed/33425879
http://dx.doi.org/10.3389/fbioe.2020.616759
work_keys_str_mv AT sunqian effectsofastragaluspolysaccharidesnanoparticlesoncerebralthrombosisinsdrats
AT shipengqiang effectsofastragaluspolysaccharidesnanoparticlesoncerebralthrombosisinsdrats
AT lincuiling effectsofastragaluspolysaccharidesnanoparticlesoncerebralthrombosisinsdrats
AT majing effectsofastragaluspolysaccharidesnanoparticlesoncerebralthrombosisinsdrats